What’s Propelling Valeant Pharmaceuticals International Inc (NYSE:VRX) After Lower Shorts Reported?

June 14, 2018 - By Robert Crowder

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Logo

Investors sentiment increased to 1.06 in Q1 2018. Its up 0.09, from 0.97 in 2017Q4. It is positive, as 29 investors sold Valeant Pharmaceuticals International, Inc. shares while 90 reduced holdings. 52 funds opened positions while 74 raised stakes. 167.32 million shares or 1.38% less from 169.66 million shares in 2017Q4 were reported.
Bancorp Of Nova Scotia has 0.08% invested in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 940,478 shares. The Michigan-based Greenleaf Tru has invested 0.01% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 25,100 were accumulated by Quinn Opportunity Partners Llc. Destination Wealth Mngmt stated it has 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Us Comml Bank De holds 16,364 shares. Company Bancorp holds 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 18,256 shares. Massmutual Fsb Adv stated it has 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Tobam invested 0.51% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Ls Investment Advisors Ltd Limited Liability Company, Michigan-based fund reported 140 shares. Tekla Cap Management Limited Liability Corporation holds 192,000 shares. Webster Bancorporation N A holds 0% or 300 shares in its portfolio. Commonwealth Bank Of Aus owns 144,560 shares. Ameriprise Financial stated it has 13,010 shares. Fmr Ltd accumulated 782,232 shares. 635,980 were accumulated by Maverick Limited.

Since March 8, 2018, it had 4 insider buys, and 0 sales for $1.20 million activity. Shares for $481,500 were bought by PAPA JOSEPH C. DE SCHUTTER RICHARD U had bought 10,000 shares worth $153,400.

The stock of Valeant Pharmaceuticals International Inc (NYSE:VRX) registered a decrease of 3.61% in short interest. VRX’s total short interest was 21.51M shares in June as published by FINRA. Its down 3.61% from 22.32 million shares, reported previously. With 6.14M shares average volume, it will take short sellers 4 days to cover their VRX’s short positions. The short interest to Valeant Pharmaceuticals International Inc’s float is 7.02%.

The stock decreased 0.26% or $0.07 during the last trading session, reaching $26.79. About 5.75M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 73.89% since June 14, 2017 and is uptrending. It has outperformed by 61.32% the S&P500.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $9.36 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 3.92 P/E ratio. Diversified Products.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 12 analysts covering Valeant Pharmaceuticals (NYSE:VRX), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Valeant Pharmaceuticals has $25.0 highest and $10.0 lowest target. $18.50’s average target is -30.94% below currents $26.79 stock price. Valeant Pharmaceuticals had 24 analyst reports since December 15, 2017 according to SRatingsIntel. H.C. Wainwright maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) rating on Tuesday, June 5. H.C. Wainwright has “Hold” rating and $2000 target. The company was maintained on Tuesday, May 8 by Cantor Fitzgerald. Piper Jaffray maintained the shares of VRX in report on Wednesday, May 9 with “Sell” rating. The rating was maintained by Canaccord Genuity on Monday, February 26 with “Hold”. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given on Tuesday, May 15 by Mizuho. RBC Capital Markets maintained it with “Hold” rating and $1800 target in Wednesday, May 2 report. Cantor Fitzgerald maintained it with “Buy” rating and $25.0 target in Friday, January 19 report. BTIG Research maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, January 17 with “Hold” rating. The firm earned “Hold” rating on Friday, April 6 by Mizuho. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Overweight” rating given on Wednesday, June 6 by Barclays Capital.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: Schaeffersresearch.com which released: “Options Bulls Blitz Booming Valeant Pharmaceuticals Stock” on June 05, 2018, also Fool.ca with their article: “Is Aurora Cannabis Inc. (TSX:ACB) Pulling a Valeant Pharmaceuticals Intl Inc. (TSX:VRX)?” published on June 14, 2018, Bizjournals.com published: “What Cindy Eckert has planned with Sprout, Addyi back in hands” on June 13, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: Seekingalpha.com and their article: “Valeant Pharmaceuticals Can Still Go Higher – Cramer’s Lightning Round (5/21/18)” published on May 22, 2018 as well as Seekingalpha.com‘s news article titled: “Valeant: Much Ado About Nothing” with publication date: May 21, 2018.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: